WellPrept Patient Education · Cancer Series

Understanding Active Surveillance

A guide for men with low-risk prostate cancer who have chosen to watch the cancer closely instead of treating it right away. Here is what the program looks like, what to expect, and how to live with it.

Version 1.0 · May 2026 Medically reviewed · Next review May 2027

Welcome

Most of us grew up with the idea that cancer is something you cut out or burn out as fast as you can. So being told you have prostate cancer, and then being told you do not have to treat it right away (and may never have to), can sound like a contradiction. For one specific group of men with low-risk disease, watching closely is the recommended care.

The cancer you have is the kind that often grows so slowly it would never have caused harm in your lifetime. Surgery or radiation now carries lasting costs to urine control and sexual function for many men. Active surveillance means watching the cancer with a set schedule of tests. It also means a clear list of reasons to switch to treatment if anything changes.

This guide is for you if you have already chosen active surveillance, or if you are leaning that way and want to know what the next years will look like. It pairs with the Localized Prostate Cancer guide, which lays out all of the treatment options side by side.

How to use this guide. Read it once at your own pace. Bring the questions in Chapter 12 to your next visit. You do not have to remember any of this. Come back to the guide whenever you need it.

Chapter 01

What active surveillance is

Active surveillance is a plan to watch your prostate cancer closely. You agree up front to switch to treatment if the cancer changes in ways your team cares about.

A structured program

Your biopsy showed prostate cancer that looks low risk under the microscope. Your urologist offered active surveillance. That is the first step for nearly all men with very low and low-risk prostate cancer, and for some men with favorable intermediate-risk disease. The major guidelines agree on this as of 2026.

You are joining a program built around a set schedule of PSA blood tests, exams, MRI scans, and biopsies. It also comes with a defined list of findings that would move you to treatment. Done well, surveillance spares you the side effects of surgery or radiation for as long as your cancer stays stable. Treatment is available the moment any of those findings show up.

Why this option exists

Many of the cancers picked up by today's PSA testing are so quiet they would never have caused harm in a man's lifetime. Some pathologists have argued the lowest-grade tumors should not even be called cancer. Treatment with surgery or radiation carries lasting costs to your urine control and your sexual function. For the lowest-risk cancers, the math favors watching closely.

What it is not

Active surveillance is different from watchful waiting. Watchful waiting is a less structured plan used for older men or men with serious other illnesses. The goal there is to manage symptoms, not to cure. There are no scheduled biopsies and no MRI. Active surveillance is for men who are still good candidates for cure. The whole point is that cure remains on the table the moment the cancer changes.

!
Active surveillance is a treatment

You will hear, often from family and friends, that watching a cancer is dangerous. For the kind of prostate cancer you have, the strongest available data says the opposite when the program is followed. Active surveillance is the recommended care, and it asks for steady follow-up over years.

Chapter 02

Who fits the program

The men who fit active surveillance share a kind of cancer that looks low risk on biopsy, MRI, and blood work. The list of who fits has grown over the past decade and continues to grow.

WatchYour biopsy report, line by lineA short video, on YouTube (youtu.be/xq0axtfSs6I)

The standard groups in 2026

  • Very low risk. Small amount of cancer, lowest grade on biopsy (Gleason 3+3), low PSA, low PSA density. Active surveillance is the recommended first step for almost every man in this group. Treatment here is almost always more than is needed.
  • Low risk. Slightly larger volume than very low risk, still lowest grade (Gleason 3+3), PSA under 10. The major guidelines list active surveillance as the preferred starting plan.
  • Favorable intermediate risk. Most often Grade Group 2 cancer (Gleason 3+4) with no other worrisome features and a small amount on biopsy. Some men land here with the lowest grade (Gleason 3+3) and either a PSA of 10 or above or a lump the urologist can feel on the exam. This is where the field is evolving fastest. More and more centers offer active surveillance to selected men in this group, especially when the MRI is clean and the tumor gene score is low.

Things that often shift the plan toward treatment

  • Cribriform pattern on biopsy. A growth pattern (the way cells line up under the microscope) that acts more aggressive than its grade. Many programs move men with cribriform off active surveillance.
  • Intraductal carcinoma on biopsy. A related finding, seen when cancer cells grow inside the small tubes of the prostate. It tends to act in a more aggressive way. This is usually a reason to treat.
  • Grade Group 3 or higher. Outside the usual active surveillance window.
  • High PSA density. Suggests more cancer than the biopsy alone captured.
  • High tumor genetic score (often called Decipher). A signal of more aggressive biology than the grade alone shows.
  • An MRI lesion that was not yet biopsied, or one that does not match the biopsy results. Often prompts a targeted re-biopsy before settling on a plan.
  • Strong family history of aggressive prostate cancer, or a known high-risk inherited gene change (such as BRCA2). Does not always block active surveillance. It does lower the bar to treat.

The part that depends on you

Active surveillance works best for men who can show up for the visits, agree to a repeat MRI and biopsy from time to time, and live with the fact that a cancer is being watched. It is a partnership with your urologist over years.

i
A fair question to ask

If you are in the favorable intermediate-risk group, ask: "Am I a fit for active surveillance, or do you want to treat me because of something on my report?"

Chapter 03

The surveillance schedule

Active surveillance uses a set list of tests on a set schedule. The tests are PSA blood draws, a yearly exam, prostate MRI every 12 to 18 months, and biopsies at defined points. Keeping these visits on the calendar is how the plan protects you.

The standard pieces

  • PSA blood test every 6 months. One high value rarely means much on its own, so your team watches the trend over time rather than any single result.
  • Digital rectal exam once a year. A gloved finger checks the back of the prostate for new firmness or change.
  • Prostate MRI every 12 to 18 months. The newer piece of the program. A steady MRI with a steady PSA lets many men push the next biopsy further out.
  • A confirmatory biopsy in the first year. A repeat biopsy, often with MRI guidance. It makes sure the first biopsy did not miss higher-grade cancer.
  • Surveillance biopsy when a test triggers it. After the first repeat biopsy, most programs do not put more biopsies on a fixed clock. New MRI changes, a PSA pattern that does not fit, or a long gap without any tissue check are the usual reasons.
  • Tumor genetic test, in some cases. A test run on the biopsy tissue (it reads the cancer's genes). Decipher is the one most used in 2026. It can help when the result is borderline. Ask if it makes sense for you.
  • Inherited gene testing, in some men. Ask to test for gene changes like BRCA2 if you have Ashkenazi Jewish roots. You should also ask if these cancers run in your family: prostate, breast, ovarian, pancreatic, or colon. A change you carry can matter for your plan and for your family.

A typical first two years on the calendar

Month 0Diagnosis. Baseline MRI if not already done. Decipher in selected cases.
Month 6PSA blood test. Brief visit.
Month 6 to 12Confirmatory biopsy, often with MRI guidance.
Month 12PSA, exam, visit.
Month 18PSA.
Month 24PSA, exam, MRI, visit.
Year 3+PSA every 6 months. Exam and MRI every 12 to 18 months. Biopsy when a result triggers it.
!
Why staying on schedule matters

Missing visits is the most common preventable failure of active surveillance. A man who skips PSA tests for two years is no longer being monitored, even if he still calls himself a surveillance patient. If a visit slips, call and reschedule it.

Chapter 04

What would change the plan

The whole point of active surveillance is that treatment stays available. These are the standard reasons your team would suggest moving from watching to treating. None of them mean the cancer has spread or that you have run out of time.

The triggers

Grade goes up
A repeat biopsy shows a higher grade than before. The single most important reason to switch. An upgrade to Grade Group 3 or higher almost always means treatment. An upgrade to a small amount of Grade Group 2 is more and more often handled with continued surveillance at expert centers.
Volume goes up
More biopsy cores show cancer than before, or a single core has a larger percentage of cancer, even at the same grade. A meaningful jump in amount can shift the plan.
MRI changes
A new lesion appears on a surveillance MRI, or a known lesion grows. A targeted biopsy of the new finding is the usual next step.
PSA pattern shifts
A PSA that climbs in a steady, unexplained way often leads to an MRI and sometimes a biopsy. Single high values are common and noisy and do not, on their own, change the plan.
Genetic signal changes
A high tumor genetic score at the start, or a worse score on a later test, can prompt earlier treatment.
You change your mind
A legitimate trigger. Some men reach a point where the worry of watching outweighs the benefit. Choosing treatment for personal reasons, after months or years of stable surveillance, is a respected decision.

What is not, by itself, a reason to switch

  • One high PSA without a trend.
  • An unclear MRI finding with stable PSA and a favorable prior biopsy. Often handled with a follow-up MRI in 6 months.
  • A small change in a single biopsy core that does not change grade or amount in a meaningful way.

About 30 to 50 out of 100 men on active surveillance for low-risk disease move to treatment over 10 to 15 years. Almost all of them can still be cured at the time they switch. The trigger system is designed to give you the safety of treatment without paying its costs until you actually need to.

Chapter 05

What the long-term data shows

The evidence base for active surveillance is now mature. Tens of thousands of men have been followed for more than a decade across several large programs and one big randomized trial. The picture is consistent.

The 15-year randomized trial (ProtecT)

A UK trial called ProtecT studied 1,643 men with PSA-detected localized prostate cancer. Each man was put at random into one of three groups: active monitoring, surgery, or radiation. At 15 years:

  • About 3 in 100 men died of prostate cancer in the monitoring group, 2 in 100 in surgery, and 3 in 100 in radiation. The gap was so small it may be due to chance.
  • Cancer spread to far parts of the body in about 9 in 100 men in monitoring, and about 5 in 100 in surgery or radiation. The numbers were small in all three groups.
  • Total deaths were similar in all three groups. Most men in the trial died of something other than prostate cancer.
  • Quality of life was where the groups split. Surgery hit urine control and sex life the hardest. Radiation had a smaller, slower effect. Monitoring spared men those costs unless they later moved to treatment.

ProtecT used an older, less intense monitoring plan than today's program. Today's plan adds MRI and tumor gene tests, which almost surely catch changes sooner. So men on a modern program can expect results at least as good as the ProtecT numbers, and likely better.

The large surveillance programs

  • Toronto group. One of the longest-running surveillance programs in the world, started in 1995. At 15 years, more than 94 in 100 men were alive without dying of prostate cancer. Most men who needed treatment were cured.
  • PRIAS. A worldwide program with over 7,000 men. About half are still on surveillance at 5 years. About 30 in 100 are still on it at 10 years.
  • Sunnybrook. Opened the program to some men with favorable intermediate-risk cancer. The 10-year results sit in the same range as the low-risk groups.

What to take from all of this

  1. For low-risk prostate cancer, active surveillance does not raise your chance of dying of the cancer. This holds true over 15 years.
  2. Surveillance has a slightly higher chance of later spread than upfront treatment, but the numbers stay small.
  3. Most men on surveillance for low-risk disease never need treatment.
  4. Of the men who do switch to treatment, most are still cured.
  5. For the right men, the years on surveillance do not seem to harm outcomes.
For low-risk prostate cancer, active surveillance gives the same long-term survival as surgery or radiation while sparing urinary and sexual side effects for as long as you stay on the program.
Chapter 06

The weight of living with cancer

Most weeks on active surveillance feel ordinary. Worry tends to rise in the days before a scan or PSA test.

The week before a PSA, MRI, or biopsy is anxious for most men on active surveillance. Scanxiety is the usual name for it. A good surveillance program treats it as part of the program rather than something to push through on your own. A few practical things make it more tolerable. Scheduling the test for early in the week shortens the wait for the result. Booking a brief follow-up call within 48 hours of the result keeps a hard number from sitting unread for days. Sometimes the worry interferes with sleep, work, or your relationships. When that happens, two or three sessions with a therapist who works with cancer patients usually helps.

What the data shows about quality of life

  • Across many studies, men on active surveillance report a good quality of life. It is much like that of men the same age who do not have prostate cancer.
  • Regret about the choice is lower in surveillance than in treatment groups. Men who picked surgery or radiation for low-risk cancer and were left with lasting urine or sex problems often regret it. Men on surveillance rarely report regret at the same level.
  • Some men on surveillance live with ongoing worry, dark thoughts about the cancer, or trouble sleeping. The worry rises around test dates and falls between them.
  • About 5 to 10 in 100 men on surveillance leave the program for worry alone, even when the tests stay steady.

What helps

  • A clear schedule. Knowing exactly when the next PSA, MRI, and visit are scheduled is itself stabilizing.
  • A clear trigger plan. Knowing in advance what would change the plan takes some of the "what if today's number is the bad one" loop out of your head.
  • Talking with your urologist about the worry. Many programs have a nurse navigator or social worker whose job is partly this.
  • Talking with another man who has been on surveillance for 5 or 10 years. Often helps more than any statistic.
  • Brief therapy. A short course of cognitive behavioral therapy works well for health worry. This is a talk therapy that retrains anxious thinking. Medicine for anxiety or low mood is sometimes the right fit too.
  • Not checking your own PSA between visits. Some men start ordering tests on their own and watch the number around the clock. It almost never helps.
i
If you are thinking about treatment for worry alone

That is a fair choice and your team should respect it. Before paying the cost of surgery or radiation, ask your team whether the worry itself can be treated first. Some men try formal anxiety care for a few months before deciding. Others know themselves and choose treatment right away. Both are reasonable.

Chapter 07

What surveillance preserves

For most men with low-risk prostate cancer, the choice between surveillance and treatment is a quality-of-life choice. Survival is similar whichever path you choose. The difference is in urine control and sexual function.

As long as you stay on the program, your urine control, erections, ejaculation, and orgasm stay at your current baseline, with the slow age-related changes that would have happened anyway. The drop in function that follows surgery or radiation only enters the picture if you eventually switch to treatment.

Side by side

FunctionActive surveillanceSurgery (radical prostatectomy)Radiation
Urine control Kept at your baseline. Most men reach pad-free or one-pad control by 12 months. About 5 to 10 in 100 have lasting leakage at one year. Usually kept. Small chance of new urgency or weak stream.
Erections Kept at your baseline. Natural age-related decline still happens. About 50 to 70 in 100 healthier younger men with nerve-sparing surgery get back erections firm enough for sex by 1 to 2 years, often with help from pills. Numbers drop with wider surgery or other health issues. New erection trouble in 30 to 50 in 100 men by 5 years, often gradual.
Ejaculation Kept. Permanently gone after surgery. Orgasm still possible but dry. Volume drops over time. Many men become dry by 5 years.
Penile length Kept. 1 to 2 cm shortening reported in 30 to 70 in 100 men. Smaller and less common shortening.
Orgasm quality Kept. Some men report changed quality or reduced intensity. A smaller group loses orgasm. Some men report a quieter or weaker orgasm.
Daily urine pattern Whatever it was, stays. Existing problems can be treated on their own. New urgency, frequency, or weak stream can show up. Usually improves over 6 to 18 months. A smaller group has lasting changes. Same as above. Some new changes can be slow to arrive and slow to fade. A small number of men develop lasting bladder irritation or occasional blood in the urine years later, called radiation cystitis.

For men whose urine control, ejaculation, and erections matter most to their quality of life, this side-by-side is the strongest case for active surveillance over upfront treatment.

Chapter 08

Habits that may tilt the odds

The evidence behind these habits is modest. Most are general health steps that also help men with prostate cancer.

Movement

This is the strongest non-medical signal in the research. Men on active surveillance who exercise often have lower rates of change in their cancer, and better survival across cancer groups overall. A simple target most teams use: about 150 minutes a week of moderate aerobic work (brisk walking counts), plus two short strength sessions. More is fine within reason.

Food

A Mediterranean-style way of eating is linked to lower prostate cancer mortality in observational studies. Think vegetables, fruits, whole grains, fish, olive oil, nuts, and less red and processed meat. Tomato-based foods, cruciferous vegetables, and green tea have weak but consistent signals. Heavy intake of processed meat and high-fat dairy is linked to more aggressive disease in some studies. No single food choice is a treatment, but these habits may shift the odds slightly in your favor.

Supplements to skip

Selenium and vitamin E supplements are not recommended. A large randomized trial called SELECT found no benefit and a possible higher risk of prostate cancer with vitamin E. Most other prostate cancer supplements have no proof behind them. Food at normal amounts is fine. Save the money you would spend at the supplement aisle.

Weight, tobacco, alcohol

  • Weight. Extra weight is linked to more aggressive prostate cancer. If you are overweight, losing 5 to 10 in 100 of your body weight is a useful goal.
  • Tobacco. Smoking is linked to a higher chance of dying of prostate cancer and worse outcomes if you ever need treatment. Quitting is the single largest health gain you can make on surveillance.
  • Alcohol. Heavy use is linked to worse outcomes. Moderate use (about one drink a day or less) does not seem to harm.

One drug class to mention to your team

If you take or start finasteride or dutasteride (often used for an enlarged prostate or for hair loss), tell your urologist. These drugs cut PSA by about half. Your team needs to know so they read your PSA trend the right way.

+
The habits that matter

No food, supplement, or workout plan will treat your prostate cancer on its own. Still, a few habits help most men, on surveillance or off. These are regular movement, a Mediterranean-style diet, a normal weight, no tobacco, and light alcohol.

Chapter 09

If the plan does change

About 30 to 50 in 100 men on active surveillance for low-risk prostate cancer eventually move to treatment over 10 to 15 years. Moving to treatment is a planned part of surveillance, not a sign that it failed. The data on outcomes after switching is reassuring.

Switching is part of the program

Many men who switch worry that the waiting cost them their chance of cure. The data do not support that worry for men on a properly run program. Most men who switch are still curable, and the years they spent on surveillance were years without surgical or radiation side effects.

What the data shows for each path after surveillance

  • Surgery after surveillance. Cancer control, clean margins, and return of urine control and erections look much like surgery picked at the start, when the switch is based on the right triggers.
  • Radiation after surveillance. Outcomes look much like radiation picked upfront. The time spent on surveillance does not seem to lower cure rates in the right men.
  • Focal therapy after surveillance. A few men grow a single main lesion that shows up on MRI. They may be a fit for a focal treatment (such as HIFU, cryotherapy, or focal laser ablation) at the time of the switch. Focal therapy is newer. The long data past 10 years is still coming in.

What the switch usually looks like

  • A restaging visit with your urologist. Often a fresh MRI and sometimes a prostate-specific membrane antigen (PSMA) PET/CT scan (a body scan that lights up prostate cancer cells).
  • A full talk about treatment choices, much like the one at first diagnosis. This time your team also has years of your own PSA, MRI, and biopsy results to work from.
  • Time to decide. Even at the switch, a same-week decision is rarely needed.
  • A second opinion is fair at this point.
  • A team visit (urology plus radiation oncology) often brings up choices a single specialty might miss.
i
One question to ask

If the day comes that your team wants to switch, ask: "What changed, and what does that change about my chance of being cured?"

Chapter 10

Telling family and friends

For many men on active surveillance, the hardest talk is the one at home. It might be with a partner, a brother on the phone, or a friend at lunch.

Why this talk is hard

Most people you tell will hear two words, prostate cancer, and picture surgery, hospital beds, and the worst version of the disease they have heard about. Their first instinct will be to push you to act. That push usually comes from love, but it can pull you toward a path you have already considered and chosen not to take.

What helps when you tell people

  • Lead with the plan, not the diagnosis. "I have a slow-growing prostate cancer that the major guidelines say should be watched, not treated right now. Here is what watching looks like."
  • Name the program out loud. Tell them about the PSA every 6 months, the MRI every year or so, the planned biopsy, and the clear list of reasons to switch.
  • Borrow the data. "A 15-year trial found that for the kind of cancer I have, watching has the same chance of dying of prostate cancer as upfront treatment, with far less effect on urine and sex."
  • Pick one person to be your full audience. A partner, an adult child, a sibling, or a close friend. Most other people only need the headline.

The talk with your partner

A partner is usually the first person to notice that you are quieter in the days before a scan. Three things tend to make the partner side of surveillance easier:

  • Bring them to at least one visit. Let your urologist explain the plan in their own words.
  • Agree on what counts as a check-in moment. Many couples decide together: "I will tell you the day before each PSA so we can both stop guessing."
  • Talk about sex. Active surveillance avoids the urinary and sexual side effects that come with surgery or radiation. Saying that out loud often makes the talk easier for both of you.

Your male relatives

Sons, brothers, and other male first-degree relatives may want to think about earlier prostate cancer screening because of your diagnosis. That talk can wait until you are ready. If your team finds an inherited gene change (such as BRCA2), the talk matters more, and your team will help you have it.

+
You set the pace

You do not owe everyone in your life this news on day one. Tell people on your timeline. Some men wait weeks or months to tell extended family. That is your call.

Chapter 11

When to call your team

Most of active surveillance is quiet. A few things should still prompt a call. The list below is short on purpose.

Same day or urgent

  • You cannot urinate, or starting a stream has suddenly become hard.
  • You have a fever after a recent prostate biopsy. Uncommon but important.
  • You have heavy bleeding from the rectum or urethra after a biopsy. (A small amount of blood in urine or semen for days to weeks after a biopsy is normal. Heavy bleeding is not.)

Reach out within days, not months

  • A PSA result you have not heard back about, or do not get.
  • A new urine symptom (going often, urgency, weak stream, blood) that does not go away.
  • A visit, MRI, or biopsy you missed and need to set up again.
  • New back pain, hip pain, or weight loss with no clear cause. The chance it is prostate cancer is low in low-risk surveillance, but your team should check it.
  • Worry that hits your sleep, your work, or your home life.

Routine

  • All planned PSA, exam, visit, MRI, and biopsy visits.
  • A yearly talk about whether the surveillance plan still fits you.
  • A talk about switching if any of the standard triggers show up (chapter 4).

The schedule at a glance

PSA every 6 months. Exam every 12 months. MRI every 12 to 18 months. A confirmatory biopsy in year 1. A surveillance biopsy when a result triggers it, or every 2 to 3 years in some programs. The success of active surveillance depends on keeping up with PSA tests, imaging, and biopsies.

!
Do not drop out without telling your team

Some men feel fine for years and stop coming in. Prostate cancer cannot be felt, so missed PSA tests, MRIs, and biopsies can hide a change for years. If you want to stop active surveillance, do it with your urologist, not by ghosting the practice.

Chapter 12

Questions to ask your team

Bring this page to your next visit. The right talk is hard to have on the spot.

About my cancer

  • What is my risk group: very low, low, or favorable intermediate?
  • I want to ask about two findings on my biopsy report. Does it mention a cribriform pattern or intraductal carcinoma? Either one can shift the plan.
  • What is my PSA density?
  • Should I have a tumor gene test like Decipher?
  • Should I see a genetic counselor to test for inherited gene changes? It would check for gene changes that run in families.

About the program

  • How often will I have a PSA, an MRI, and a biopsy?
  • When is my confirmatory biopsy planned?
  • Who do I call if I miss a visit or have a question between visits?
  • Do you have a nurse navigator I can meet?

About what would change the plan

  • What would trigger you to recommend treatment?
  • What does my PSA trend look like so far?
  • Has my MRI changed?
  • If you ever recommend a switch, which treatments would I still be able to choose?

About living with this

  • What can I do on my own that might help?
  • Any workouts, foods, or supplements you do suggest, and any I should skip?
  • How should I tell my partner, my adult kids, or my brother?
  • What kind of support is there for the worry between visits?

About the long view

  • Based on my situation, what is the chance I will eventually need treatment?
  • If I do need treatment one day, what does the data say about cure rates after a stretch on surveillance?
  • Is my case ever reviewed at a tumor board, and is that something I should ask for?
Chapter 13

Words to know

The Localized Prostate Cancer guide covers the general prostate cancer terms: PSA, Gleason, risk groups, and the MRI score. That MRI score is the Prostate Imaging Reporting and Data System (PI-RADS). These are the words used most in active surveillance.

Active surveillance
A structured plan of PSA tests, exams, MRI, and periodic biopsies, with a clear plan to switch to treatment if the cancer changes.
Watchful waiting
A less structured observation, used in older men or men with serious other illness. The goal is comfort, not cure. Different from active surveillance.
Confirmatory biopsy
A repeat biopsy in the first 6 to 12 months of surveillance, to confirm the first biopsy did not miss higher-grade cancer.
Surveillance biopsy
A biopsy done during surveillance in response to a trigger or on a fixed program schedule.
Targeted biopsy
Biopsy cores aimed at a specific lesion seen on MRI, using image fusion.
Trigger
A finding (grade goes up, more cancer on biopsy, MRI change, PSA pattern) that prompts treatment from surveillance.
Switch to treatment
Sometimes called conversion. The move from surveillance to active treatment.
Reclassification
A change in the cancer's apparent grade or volume, often based on a new biopsy.
PSA density
PSA divided by prostate volume. Helps tell PSA from enlarged prostate apart from PSA from cancer.
PSA velocity
How fast PSA is rising over time. Noisy. Not a single trigger by itself in modern surveillance.
PSA doubling time
The time it takes PSA to double. Treated today as one input among several, not a hard rule.
Decipher score
A tumor genetic classifier. The most NCCN-integrated risk-refinement tool for surveillance as of 2026.
Prolaris
A different tumor genetic test used in some programs.
Oncotype DX
A tumor genetic test used in some programs.
Cribriform pattern
An aggressive microscopic growth pattern on biopsy. Often a reason to leave surveillance even within Grade Group 2.
Intraductal carcinoma
A related aggressive feature. Usually a reason to treat.
PI-RADS
A scoring system for prostate MRI: 1 (unlikely cancer) to 5 (likely cancer).
Scanxiety
Informal term for the worry that builds in the days before a scan or PSA result.
Decision regret
A measure of how much a person regrets a treatment choice. Lower in surveillance than in upfront treatment for low-risk disease.
Multiparametric MRI
The standard prostate MRI used in surveillance. Combines several types of images to spot suspicious areas.
Tumor board
A meeting where urologists, radiation oncologists, pathologists, and others review a case together.
BRCA2 and related genes
Inherited gene changes (such as BRCA2, ATM, CHEK2, PALB2) that can run in families and may change your surveillance plan.
Sources

Sources and further reading

This guide draws on current society guidelines and the major trials and long-running programs behind today's surveillance practice. The list below points to where you can read more.

  1. NCCN Prostate Cancer Guidelines. nccn.org
  2. NCCN Patient Guidelines: Prostate Cancer. nccn.org/patients
  3. EAU Prostate Cancer Guidelines. uroweb.org
  4. ProtecT trial, 15-year results (Hamdy et al., NEJM 2023). nejm.org
  5. ProtecT trial, 10-year results (Hamdy et al., NEJM 2016). nejm.org
  6. PRIAS active surveillance program. prias-project.org
  7. Toronto active surveillance cohort (Klotz, JCO). ascopubs.org
  8. Decipher genomic classifier in prostate cancer. decipherbio.com
  9. SELECT trial: vitamin E and selenium. jamanetwork.com
  10. NCI: Prostate Cancer Treatment. cancer.gov
  11. American Cancer Society: Active Surveillance. cancer.org
  12. Prostate Cancer Foundation: Active Surveillance. pcf.org
  13. National Society of Genetic Counselors (find a counselor). nsgc.org
  14. ClinicalTrials.gov. clinicaltrials.gov

Always work through your own situation with your care team. Use this guide to prepare for those conversations.

Playing audio...